Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3Neoplasms 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Liver Metastasis Colon Cancer 1Kidney Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

Sorafenib 7Radiosurgery 6Bevacizumab 6pembrolizumab 4Oxaliplatin 4Cryosurgery 4atezolizumab 3Radiotherapy, Conformal 3Nivolumab 3Ipilimumab 3Fluorouracil 3Cyclophosphamide 3tremelimumab 2spartalizumab 2lenvatinib 2fludarabine 2Leucovorin 2Injections 2Gemcitabine 2Everolimus 2Epirubicin 2Doxorubicin 2Celecoxib 2Carboplatin 2Capecitabine 2yttrium chloride 1vofatamab 1toripalimab 1tocilizumab 1sapanisertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Liver Neoplasms × Electroporation × Clear all
NCT03183219 2020-07-13

Safety and Efficiency of γδ T Cell Against Liver Cancer

Fuda Cancer Hospital, Guangzhou

Phase 1/2 Completed
30 enrolled
Gastrointestinal

Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡